Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 6/20 | 0.50 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.50 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | LAP3 | P28838 | 4/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11423582 | 0.97 | ANPEP (0.48) | ANPEPERAP1ERAP2TSHRCYP3A4 | |
| SCHEMBL1006494 | 0.91 | TSHR (0.41) | ANPEPERAP1ERAP2TSHRCYP3A4 | |
| SCHEMBL56311 | 0.84 | ANPEP (0.65) | ANPEPERAP1ERAP2TSHRCYP3A4 | |
| SCHEMBL10343746 | 0.81 | ANPEP (0.61) | ANPEPERAP1ERAP2TSHRCYP3A4 | |
| Hydrochloric Acid SCHEMBL56763 | 0.81 | GMNN (0.63) | ANPEPERAP1ERAP2TSHRCYP3A4 | |
| SCHEMBL24771445 | 0.78 | ANPEP (0.46) | ANPEPERAP1ERAP2TSHRCYP3A4 | |
| SCHEMBL21676015 | 0.78 | TSHR (0.32) | TSHRTDP1ALDH1A1 | |
| SCHEMBL17766840 | 0.77 | TSHR (0.47) | ANPEPERAP1ERAP2TSHRCYP3A4 | |
| SCHEMBL15658 | 0.77 | — | — | |
| SCHEMBL1090210 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180110757-A1 | METHODS OF TREATING PRURITIS AND PAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-04-26 | — | — | US | disclosed |
| US-20140107153-A1 | THERAPEUTIC QUINOLINE AND NAPHTHALENE DERIVATIVES | ALLERGAN, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140011771-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING PAIN | ALLERGAN, INC. (US) | 2014-01-09 | — | — | US | disclosed |
| US-20130079290-A1 | S1P ANTAGONISTS AS ADJUNCT OCULAR HYPOTENSIVES | ALLERGAN, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-8143291-B2 | Indole compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor biological activity | ALLERGAN, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20120071448-A1 | S1P3 Receptor Inhibitors for Treating Conditions of the Eye | ALLERGAN, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110275677-A1 | INDOLE COMPOUNDS BEARING ARYL OR HETEROARYL GROUPS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110046177-A1 | THERAPEUTIC QUINOLINE AND NAPHTHALENE DERIVATIVES | ALLERGAN, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110009453-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING INFLAMMATION | DONELLO JOHN E | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011771-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING PAIN | S1PR3, LPAR3, S1PR2 | ANPEP 2238/4885ERAP1 3529/4885ERAP2 3035/4885 |
| US-20110275677-A1 | INDOLE COMPOUNDS BEARING ARYL OR HETEROARYL GROUPS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR BIOLOGICAL ACTIVITY | S1PR1, S1PR3, S1PR2 | ANPEP 2756/4885ERAP1 2499/4885ERAP2 2652/4885 |
| US-20110009453-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING INFLAMMATION | S1PR3, S1PR1, S1PR2 | ANPEP 2459/4885ERAP1 2307/4885ERAP2 2298/4885 |
| US-20140107153-A1 | THERAPEUTIC QUINOLINE AND NAPHTHALENE DERIVATIVES | NQO1, GOT2, NDUFA7 | ANPEP 3414/4885ERAP1 3122/4885ERAP2 1843/4885 |
| US-20120071448-A1 | S1P3 Receptor Inhibitors for Treating Conditions of the Eye | S1PR3, S1PR1, S1PR2 | ANPEP 2995/4885ERAP1 2814/4885ERAP2 2548/4885 |
| US-20130079290-A1 | S1P ANTAGONISTS AS ADJUNCT OCULAR HYPOTENSIVES | S1PR3, S1PR5, S1PR2 | ANPEP 2690/4885ERAP1 2820/4885ERAP2 2588/4885 |
| US-20110046177-A1 | THERAPEUTIC QUINOLINE AND NAPHTHALENE DERIVATIVES | NDUFA7, NQO1, NDUFA2 | ANPEP 3256/4885ERAP1 2987/4885ERAP2 1943/4885 |
| US-20180110757-A1 | METHODS OF TREATING PRURITIS AND PAIN | CYSLTR2, LTB4R2, CYSLTR1 | ANPEP 1765/4885ERAP1 3007/4885ERAP2 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.